As their mandate to give back to society, HPE India has installed over 130 eHealth Centers (eHC) under its Corporate Social Responsibility program, across the country where more than 1 million patients have been registered and treated under primary health domain, free of cost.

After signing the Corporate TB Pledge, HPE India aligned its CSR work with the government’s goal to eliminate TB. In July 2019, HPE India signed the Corporate TB Pledge and committed to screen fifty thousand presumptive patients for TB using their existing set up of eHC’s across 9 locations in India.

HPE aims to target the “Missing TB” cases who carry the disease and may go undiagnosed for a longer period. It further aims to refer the diagnosed patients to nearest DOTS Program. This is being achieved with joint cooperation between Ministry of Health and Family Welfare, USAID and The Union.

The India Health Fund (IHF), a collaborative initiative led by the Tata Trusts, endeavors to leverage the power of collective impact to eliminate Tuberculosis (TB) by 2025 and malaria by 2030 from India. IHF collaborates with donors and investors to share investment decisions to support strategic projects and solutions aimed at the elimination of TB and malaria. It provides the platform to raise resources and channel the same towards supporting breakthrough innovations, which will help accelerate the removal of these infectious diseases. IHF has a formal engagement with the Central TB Division, The Global Fund, Indian Council of Medical Research, India TB Research Consortium, STOP TB Partnership, National Institute of Tuberculosis and Respiratory Diseases and other similar organizations.

TB continues to be a major health challenge in India. Active Case Finding is the key to identifying high-risk cases in the community. Identification of high-risk cases followed by diagnosis, awareness building, and treatment could prevent further spread of the infection, particularly in vulnerable age groups. Mylan, a global company, therefore, undertook a project aimed at supporting India’s mission to eliminate TB by 2025.

Senapati district in Manipur is known for its lush green valleys, deep gorges and crystal clear rivers. However, the flip side to its idyllic beauty is the difficult daily lives of its inhabitants, who have to trudge several kilometres until they can access even the most basic of facilities. Even with one Community Health Center and two Primary Health Centers in the Mao block of Senapati district, the difficult terrain makes it difficult for the population of 41,000 people across 26 villages to access health care. Conducting awareness campaigns and encouraging patients to access healthcare facilities in itself is a huge challenge.

While in big cities, several private enterprises support government’s TB program, Senapati region with a forest cover was often overlooked. This is when J.V. Gokal Charity Trust (JVGCT), NGO based in Maharashtra, decided to intervene.

Johnson & Johnson believes good health is the foundation of vibrant lives, thriving communities and forward progress. Over the last 70 years in India, it has improved the health and well-being of people by providing Consumer Healthcare, Medical Devices and Pharmaceuticals. Committed to supporting the Government of India in realizing its vision of a TB-free India by 2025, it has been working with the Government and other partners to take a holistic approach to eliminate TB.

Growing resistance to the most commonly used drugs compounds the public health challenge of TB, with 66,359 MDR-TB cases registered across India in 2019. Improvements in diagnosis and treatment rates are needed to help control the TB epidemic.

Becton Dickinson (BD) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. In India, BD has nearly 1000 associates working across 700 cities and towns. They have successfully developed technology that helps in diagnosis of TB drug sensitivity. This helps clinicians prescribe appropriate anti-tubercular drugs, which in turn helps in combating multi-drug resistance TB. These are the BACTEC MGIT automated mycobacterial detection system. Over 100 of these fully automated solution for mycobacterial liquid culture and susceptibility testing have already been installed in India.

Uttar Pradesh has the highest TB burden in the country, with over 486,000 new cases being reported in 2019. The residents of villages near GAIL’s “Pata Petrochemical complex,” named after a small village Pata in the district Auraiya, have always needed an anchoring entity for community outreach that would link them to the government facilities. Even for TB elimination — right from active case-finding to accurate diagnosis, treatment, counseling, and nutritional support – the community needed hand-holding to access the services offered by the national TB program.